[
  {
    "ts": null,
    "headline": "JPM26: Pfizer’s Metsera deal supercharges its obesity strategy",
    "summary": "Pfizer CEO Bourla anticipates that the obesity market will “grow very fast” and reach $150bn by 2030.",
    "url": "https://finnhub.io/api/news?id=c4e9b42ae7a276a4e6aadbd17b053deda6f8cfd40418603defc5d9f182842cb9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768333836,
      "headline": "JPM26: Pfizer’s Metsera deal supercharges its obesity strategy",
      "id": 138092352,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer CEO Bourla anticipates that the obesity market will “grow very fast” and reach $150bn by 2030.",
      "url": "https://finnhub.io/api/news?id=c4e9b42ae7a276a4e6aadbd17b053deda6f8cfd40418603defc5d9f182842cb9"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer CEO Says Company Is Pushing for FDA Priority Review Voucher",
    "summary": "Albert Bourla said Pfizer has discussed a fast-pass voucher with the White House during the JPMorgan Healthcare Conference.",
    "url": "https://finnhub.io/api/news?id=ed422d19338aff3c1b86947408258e9f9365293fd1fe2f2799ab544742c19bc1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768327229,
      "headline": "Pfizer CEO Says Company Is Pushing for FDA Priority Review Voucher",
      "id": 138086809,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Albert Bourla said Pfizer has discussed a fast-pass voucher with the White House during the JPMorgan Healthcare Conference.",
      "url": "https://finnhub.io/api/news?id=ed422d19338aff3c1b86947408258e9f9365293fd1fe2f2799ab544742c19bc1"
    }
  },
  {
    "ts": null,
    "headline": "ABBV Inks Drug Pricing Deal With Trump, Joins PD-1xVEGF Bandwagon",
    "summary": "AbbVie strikes a Trump drug-pricing pact and a $5.6B cancer licensing deal, cutting U.S. prices while expanding its oncology pipeline.",
    "url": "https://finnhub.io/api/news?id=e0f59a733f7b0042c09c23bb836a391779a36876afcc394917e5fbad77f50f3d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768325700,
      "headline": "ABBV Inks Drug Pricing Deal With Trump, Joins PD-1xVEGF Bandwagon",
      "id": 138087373,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "AbbVie strikes a Trump drug-pricing pact and a $5.6B cancer licensing deal, cutting U.S. prices while expanding its oncology pipeline.",
      "url": "https://finnhub.io/api/news?id=e0f59a733f7b0042c09c23bb836a391779a36876afcc394917e5fbad77f50f3d"
    }
  },
  {
    "ts": null,
    "headline": "Bipolar Disorder Market Opportunity Assessment and Forecast Report 2024-2034 Featuring Johnson & Johnson, Otsuka, AbbVie, Bristol Myers-Squibb, OWP, Sumitomo, Pfizer",
    "summary": "Key market opportunities in the Bipolar Disorder market include developing targeted treatments for bipolar depression due to current unmet needs, capitalizing on late-stage pipeline products projected to influence market growth, and leveraging strategic partnerships and emerging players with strong portfolios.Dublin, Jan. 13, 2026 (GLOBE NEWSWIRE) -- The \"Bipolar Disorder: Opportunity Assessment and Forecast\" report has been added to ResearchAndMarkets.com's offering.This report covers the 7MM a",
    "url": "https://finnhub.io/api/news?id=3a3be8bfce30960c5d0a724a301e91e201d0fb9c1926dbb97f726033c338007a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768321260,
      "headline": "Bipolar Disorder Market Opportunity Assessment and Forecast Report 2024-2034 Featuring Johnson & Johnson, Otsuka, AbbVie, Bristol Myers-Squibb, OWP, Sumitomo, Pfizer",
      "id": 138086646,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Key market opportunities in the Bipolar Disorder market include developing targeted treatments for bipolar depression due to current unmet needs, capitalizing on late-stage pipeline products projected to influence market growth, and leveraging strategic partnerships and emerging players with strong portfolios.Dublin, Jan. 13, 2026 (GLOBE NEWSWIRE) -- The \"Bipolar Disorder: Opportunity Assessment and Forecast\" report has been added to ResearchAndMarkets.com's offering.This report covers the 7MM a",
      "url": "https://finnhub.io/api/news?id=3a3be8bfce30960c5d0a724a301e91e201d0fb9c1926dbb97f726033c338007a"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer Says “I’m a Eli Lilly Guy” When Asked About Viking Therapeutics",
    "summary": "Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the stocks Jim Cramer discussed, along with recent market rotation. When a caller asked about the stock, here’s what Cramer had to say in response: “Okay, no, look, I’m a Eli Lilly guy, okay? I’m going to stick with it. If I’m going to do Viking, I’m going […]",
    "url": "https://finnhub.io/api/news?id=37a6aea0c34cabcbfacb16e19ab25780377cc295fc7d90b24ae0b06f0c7514fe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768313179,
      "headline": "Jim Cramer Says “I’m a Eli Lilly Guy” When Asked About Viking Therapeutics",
      "id": 138084483,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the stocks Jim Cramer discussed, along with recent market rotation. When a caller asked about the stock, here’s what Cramer had to say in response: “Okay, no, look, I’m a Eli Lilly guy, okay? I’m going to stick with it. If I’m going to do Viking, I’m going […]",
      "url": "https://finnhub.io/api/news?id=37a6aea0c34cabcbfacb16e19ab25780377cc295fc7d90b24ae0b06f0c7514fe"
    }
  },
  {
    "ts": null,
    "headline": "Will AbbVie's Oncology Segment Support Top-line Growth in Q4 Earnings?",
    "summary": "ABBV's oncology unit is expected to post nearly 4% Q4 sales growth, as newer drugs offset weakness from declining Imbruvica demand.",
    "url": "https://finnhub.io/api/news?id=deaeebebd40a90e35b35a7807231ba998ff3cd4cb2bcc9a1b6aac5bf5c585504",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768311780,
      "headline": "Will AbbVie's Oncology Segment Support Top-line Growth in Q4 Earnings?",
      "id": 138086668,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "ABBV's oncology unit is expected to post nearly 4% Q4 sales growth, as newer drugs offset weakness from declining Imbruvica demand.",
      "url": "https://finnhub.io/api/news?id=deaeebebd40a90e35b35a7807231ba998ff3cd4cb2bcc9a1b6aac5bf5c585504"
    }
  },
  {
    "ts": null,
    "headline": "Inside Pfizer's Oncology Performance Ahead of Q4 Results",
    "summary": "PFE's oncology results should reflect steady growth from Seagen ADCs and key brands, offset by pricing and competitive pressures.",
    "url": "https://finnhub.io/api/news?id=4bbd2e0d05be89da16efff4aa039eb3fbef25f9109658ddf301a26ce3cc78431",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768308840,
      "headline": "Inside Pfizer's Oncology Performance Ahead of Q4 Results",
      "id": 138084496,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "PFE's oncology results should reflect steady growth from Seagen ADCs and key brands, offset by pricing and competitive pressures.",
      "url": "https://finnhub.io/api/news?id=4bbd2e0d05be89da16efff4aa039eb3fbef25f9109658ddf301a26ce3cc78431"
    }
  },
  {
    "ts": null,
    "headline": "Tempus AI (TEM) Soars 15% on $1.1-Billion Deal",
    "summary": "We recently published 10 Stocks With Crazy Gains. Tempus AI Inc. (NASDAQ:TEM) was one of the top performers on Monday. Tempus AI snapped a two-day losing streak on Monday, soaring by as much as 15 percent to $76.33 apiece, as investors took heart from a strong demand for its services, having bagged $1.1 billion in […]",
    "url": "https://finnhub.io/api/news?id=61ced03819d123ffc8f14f81ba7966cc2bbf9d87fe288f30c95e6fc3e0d47295",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768308508,
      "headline": "Tempus AI (TEM) Soars 15% on $1.1-Billion Deal",
      "id": 138083148,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "We recently published 10 Stocks With Crazy Gains. Tempus AI Inc. (NASDAQ:TEM) was one of the top performers on Monday. Tempus AI snapped a two-day losing streak on Monday, soaring by as much as 15 percent to $76.33 apiece, as investors took heart from a strong demand for its services, having bagged $1.1 billion in […]",
      "url": "https://finnhub.io/api/news?id=61ced03819d123ffc8f14f81ba7966cc2bbf9d87fe288f30c95e6fc3e0d47295"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Roundup: Market Talk",
    "summary": "Find insight on Bristol-Myers Squibb, Pfizer, Johnson & Johnson and more in the latest Market Talks covering Health Care.",
    "url": "https://finnhub.io/api/news?id=2b7695e2beedfa3ea8c953ed19767036b271ccd1aaba133d4bb2087f5d213804",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768305180,
      "headline": "Health Care Roundup: Market Talk",
      "id": 138083149,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Find insight on Bristol-Myers Squibb, Pfizer, Johnson & Johnson and more in the latest Market Talks covering Health Care.",
      "url": "https://finnhub.io/api/news?id=2b7695e2beedfa3ea8c953ed19767036b271ccd1aaba133d4bb2087f5d213804"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. (NYSE:PFE) is favoured by institutional owners who hold 66% of the company",
    "summary": "Key Insights Given the large stake in the stock by institutions, Pfizer's stock price might be vulnerable to their...",
    "url": "https://finnhub.io/api/news?id=dcbefd09520c50c6d2a7d4d60443fa325d36fd18dd95e84462f83059942683b3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768302020,
      "headline": "Pfizer Inc. (NYSE:PFE) is favoured by institutional owners who hold 66% of the company",
      "id": 138083453,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Key Insights Given the large stake in the stock by institutions, Pfizer's stock price might be vulnerable to their...",
      "url": "https://finnhub.io/api/news?id=dcbefd09520c50c6d2a7d4d60443fa325d36fd18dd95e84462f83059942683b3"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Strikes a $100 Billion Deal With Trump. How the Drugmaker Will Dodge Tariffs.",
    "summary": "AbbVie  has agreed to cut some drug prices and invest $100 billion in the U.S. in exchange for an exemption from some tariffs.  The pharma company said in a statement late Monday that it had struck a deal with the Trump administration to lower Medicaid prices and pour the money into U.S. research and development.  AbbVie will also expand its direct-to-patient offerings of certain drugs on the government portal TrumpRx.",
    "url": "https://finnhub.io/api/news?id=e703854b3b85d22e1a0a8c62c02820a8ea079b07155cfe39db7ccb9a8b6421b7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768299840,
      "headline": "AbbVie Strikes a $100 Billion Deal With Trump. How the Drugmaker Will Dodge Tariffs.",
      "id": 138083151,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "AbbVie  has agreed to cut some drug prices and invest $100 billion in the U.S. in exchange for an exemption from some tariffs.  The pharma company said in a statement late Monday that it had struck a deal with the Trump administration to lower Medicaid prices and pour the money into U.S. research and development.  AbbVie will also expand its direct-to-patient offerings of certain drugs on the government portal TrumpRx.",
      "url": "https://finnhub.io/api/news?id=e703854b3b85d22e1a0a8c62c02820a8ea079b07155cfe39db7ccb9a8b6421b7"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer's Patent Cliff, Rising Debt, And The Fight To Stay A Buy",
    "summary": "Pfizer's Patent Cliff, Rising Debt, And The Fight To Stay A Buy",
    "url": "https://finnhub.io/api/news?id=077787b658253f61ff4e8258fa6ac2b835dfe4a8bf2f9eaf07a6078076f5554c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768284708,
      "headline": "Pfizer's Patent Cliff, Rising Debt, And The Fight To Stay A Buy",
      "id": 138082201,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=077787b658253f61ff4e8258fa6ac2b835dfe4a8bf2f9eaf07a6078076f5554c"
    }
  },
  {
    "ts": null,
    "headline": "Top Picks 2026- Pfizer Inc. PFE",
    "summary": "As we head into 2026, healthcare stands out as one of the most dislocated areas of the market. One of our favorite ideas within the sector is Pfizer Inc. (PFE), an iconic American blue chip that has climbed its own crowded wall of worry on top of the broader healthcare exodus, advises Tom Hayes, editor of HedgeFundTips.",
    "url": "https://finnhub.io/api/news?id=b02751b1afc7a9aba45cbe0cc9b9a3f1a60eb9a7c671fbd3ea88b87a5f0fb8f6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768280460,
      "headline": "Top Picks 2026- Pfizer Inc. PFE",
      "id": 138092362,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "As we head into 2026, healthcare stands out as one of the most dislocated areas of the market. One of our favorite ideas within the sector is Pfizer Inc. (PFE), an iconic American blue chip that has climbed its own crowded wall of worry on top of the broader healthcare exodus, advises Tom Hayes, editor of HedgeFundTips.",
      "url": "https://finnhub.io/api/news?id=b02751b1afc7a9aba45cbe0cc9b9a3f1a60eb9a7c671fbd3ea88b87a5f0fb8f6"
    }
  },
  {
    "ts": null,
    "headline": "3 Value Stocks That Fall Short",
    "summary": "Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.",
    "url": "https://finnhub.io/api/news?id=ed2f0d28d035932510c461684076877b2eb5c3c65a00b636d951b4295de81068",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768278784,
      "headline": "3 Value Stocks That Fall Short",
      "id": 138086812,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.",
      "url": "https://finnhub.io/api/news?id=ed2f0d28d035932510c461684076877b2eb5c3c65a00b636d951b4295de81068"
    }
  },
  {
    "ts": null,
    "headline": "Adaptive Biotechnologies Touts clonoSEQ MRD Growth, Targets Companywide Profitability in 2026",
    "summary": "Adaptive Biotechnologies (NASDAQ:ADPT) used a presentation at the J.P. Morgan healthcare conference to outline growth drivers for its clonoSEQ minimal residual disease (MRD) franchise and to describe a capital-disciplined strategy for its immune medicine (IM) unit, while also reiterating an expectat",
    "url": "https://finnhub.io/api/news?id=ad211edcc79beec1f4c0d1e25ecfe1bcfcb276be9b97c69573d647f77e7dee2b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768270004,
      "headline": "Adaptive Biotechnologies Touts clonoSEQ MRD Growth, Targets Companywide Profitability in 2026",
      "id": 138083455,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Adaptive Biotechnologies (NASDAQ:ADPT) used a presentation at the J.P. Morgan healthcare conference to outline growth drivers for its clonoSEQ minimal residual disease (MRD) franchise and to describe a capital-disciplined strategy for its immune medicine (IM) unit, while also reiterating an expectat",
      "url": "https://finnhub.io/api/news?id=ad211edcc79beec1f4c0d1e25ecfe1bcfcb276be9b97c69573d647f77e7dee2b"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. (PFE) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow",
    "summary": "2026-01-13. The following slide deck was published by Pfizer Inc.",
    "url": "https://finnhub.io/api/news?id=9cdf2798ad996dcd8cf30659bb71f59fe3d9dae884aca790b6f5d77b0a65c482",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768264247,
      "headline": "Pfizer Inc. (PFE) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow",
      "id": 138080489,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "2026-01-13. The following slide deck was published by Pfizer Inc.",
      "url": "https://finnhub.io/api/news?id=9cdf2798ad996dcd8cf30659bb71f59fe3d9dae884aca790b6f5d77b0a65c482"
    }
  }
]